TAGAMET Drug Patent Profile
✉ Email this page to a colleague
When do Tagamet patents expire, and what generic alternatives are available?
Tagamet is a drug marketed by Glaxosmithkline and Medtech Products and is included in six NDAs.
The generic ingredient in TAGAMET is cimetidine. There are twenty-five drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the cimetidine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tagamet
A generic version of TAGAMET was approved as cimetidine by MYLAN on May 17th, 1994.
Summary for TAGAMET
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 178 |
Clinical Trials: | 6 |
Patent Applications: | 6,565 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TAGAMET |
What excipients (inactive ingredients) are in TAGAMET? | TAGAMET excipients list |
DailyMed Link: | TAGAMET at DailyMed |
Recent Clinical Trials for TAGAMET
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Early Phase 1 |
Washington State University | Early Phase 1 |
National Institutes of Health (NIH) | Early Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for TAGAMET
US Patents and Regulatory Information for TAGAMET
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | TAGAMET | cimetidine hydrochloride | INJECTABLE;INJECTION | 017939-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Medtech Products | TAGAMET HB | cimetidine | TABLET;ORAL | 020238-001 | Jun 19, 1995 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glaxosmithkline | TAGAMET | cimetidine | TABLET;ORAL | 017920-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Medtech Products | TAGAMET HB | cimetidine | TABLET;ORAL | 020238-002 | Aug 21, 1996 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TAGAMET
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline | TAGAMET | cimetidine hydrochloride | SOLUTION;ORAL | 017924-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | TAGAMET | cimetidine hydrochloride | SOLUTION;ORAL | 017924-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | TAGAMET | cimetidine | TABLET;ORAL | 017920-002 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | TAGAMET | cimetidine hydrochloride | INJECTABLE;INJECTION | 017939-002 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TAGAMET
See the table below for patents covering TAGAMET around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Switzerland | 578583 | ⤷ Try a Trial | |
Netherlands | 162073 | ⤷ Try a Trial | |
United Kingdom | 1395929 | ⤷ Try a Trial | |
Egypt | 10876 | PROCESS FOR PRODUCTION OF PHARMACEUTICALLY ACTIVE ALKYL THIOUREA UREA AND GUANIDINE COMPOUNDS | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |